Irish Irish
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Nuacht is Déanaí

Teiripe Céad Ghéine do Dhaoine Fásta a bhfuil Haemaifilia A Géar orthu, ROCTAVIAN™ BioMarin Faofa ag an gCoimisiún Eorpach (CE)

 

Faigheann BioMarin Tuairim Dhearfach CHMP san Eoraip maidir le Teiripe Géine Valoctocogene Roxaparvovec chun Daoine Fásta a Chaitheamh le Haemaifilia Trom A

 

Sonraí Cliniciúla Tosaigh Dearfacha ón Triail Daingnithe Dáileog-B-LIEVE do FLT180a i Hemophilia B Arna chur i láthair ag Comhdháil an Chumainn Idirnáisiúnta um Thrombosis agus Haemostasis

 

Cuireann Freeline tús le Dáileog an Dara Cohórt i dTriail Daingnithe Dáileog B-LIEVE de FLT180a i Haemaifilia B

 

Ar ais go barr
Íomha

Please enable the javascript to submit this form

Maidir

Le tacaíocht ó dheontais oideachais ó Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, agus uniQure, Inc.

Riachtanach SSL